Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amy Oppenheim"'
Autor:
Bethany N. Smith, Rajeev Mishra, Sandrine Billet, Veronica R. Placencio-Hickok, Minhyung Kim, Le Zhang, Frank Duong, Anisha Madhav, Kevin Scher, Nancy Moldawer, Amy Oppenheim, Bryan Angara, Sungyong You, Mourad Tighiouart, Edwin M. Posadas, Neil A. Bhowmick
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 31(1)
Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7, expression as a recognized means
Autor:
Hsian-Rong Tseng, Alexander Montes, Amy Oppenheim, Margarit Sievert, Ann Go, Alexander Ureno, Neil A. Bhowmick, Yi-Tsung Lu, Suwicha Limvorasak, Karen A. Cavassani, Robert A. Figlin, Manisha Tripathi, Edwin M. Posadas, Andre Rogatko, Leland W.K. Chung, Jie-Fu Chen, Nancy P. Moldawer
Publikováno v:
Journal of Clinical Oncology. 35:5031-5031
5031 Background: The presence of VM in metastatic, castration-resistant prostate cancer (mCRPC) predicts poor survival. Cabozantinib (cabo) is a multi-kinase inhibitor that has clinical activity that did not improve survival in an unselected mCRPC po
Autor:
Daniel H.S. Silverman, Sonia Ancoli-Israel, Patricia A. Ganz, Thomas R. Belin, Lorna Kwan, Michael R. Irwin, Steven A. Castellon, Julienne E. Bower, Amy Oppenheim, Steve W. Cole
Publikováno v:
Journal of the National Cancer Institute. 105(11)
Cognitive impairment is a feared complication of cancer treatment (1–4) and has been extensively studied in breast cancer patients (5–16). Subjective cognitive complaints have been a driving force behind research in this area since the late 1990s
Autor:
Edwin M. Posadas, Kevin Scher, Jie-Fu Chen, Margarit Sievert, Amy Oppenheim, Nancy P. Moldawer, Beatrice Knudsen, Michael Freeman, Neil Bhowmick, Andre Rogatko, Hsian-Rong Tseng, Leland WK Chung, Robert A. Figlin
Publikováno v:
Journal of Clinical Oncology. 34:e16552-e16552
Autor:
Amy Oppenheim, Margarit Sievert, Jie-Fu Chen, Neil A. Bhowmick, Richard Huynh, Hsian-Rong Tseng, Michael R. Freeman, Andre Rogatko, Robert A. Figlin, Edwin M. Posadas, Beatrice S. Knudsen, Leland W.K. Chung, Mourad Tighiouart, Kevin Scher, Nancy P. Moldawer
Publikováno v:
Journal of Clinical Oncology. 34:208-208
208 Background: Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that has recognized clinical activity in mCRPC. While phase 3 studies did not show a significant improvement in overall survival (OS), patients with VM had improved OS c
Autor:
Hsian-Rong Tseng, Michael R. Freeman, Andre Rogatko, Robert A. Figlin, Edwin M. Posadas, Beatrice S. Knudsen, Amy Oppenheim, L. Green, Kevin Scher, Dolores Di Vizio, Mourad Tighiouart, Margarit Sievert, Leland W.K. Chung, Yi-Tsung Lu, Nancy P. Moldawer, David M. J. Hoffman, Neil A. Bhowmick
Publikováno v:
Annals of Oncology. 25:iv547
Aim: Cabozantinib (XL184) is a potent multi-targeted tyrosine kinase inhibitor (TKI) that is under active investigation in several malignancies including prostate cancer (PC). The mechanism of action in PC has not been well characterized at this time
Autor:
Leland Green, Edwin M. Posadas, Dolores Di Vizio, Beatrice S. Knudsen, Margarit Sievert, Yi-Tsung Lu, Mourad Tighgohart, Hsian-Rong Tseng, Leland W.K. Chung, Michael R. Freeman, Andre Rogatko, Robert A. Figlin, Neil A. Bhowmick, Nancy P. Moldawer, David M. J. Hoffman, Amy Oppenheim
Publikováno v:
Journal of Clinical Oncology. 32:e16080-e16080
e16080 Background: Cabozantinib (XL184) is a potent multi-targeted tyrosine kinase inhibitor (TKI) that is under active investigation in several malignancies including prostate cancer (PC). The mec...